B. Johnson

Most-cited papers

1. P2.01-17 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Pts

   E. Felip, G. Castro, A. Greystoke, B. Solomon +5 more

   2019Journal of Thoracic Oncology1 citations Open access

   Semantic Scholar

   Save

2. PD01.05 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients

   B. Johnson, G. Castro, A. Greystoke, B. Solomon +5 more

   2019Journal of Thoracic Oncology0 citations Open access

   Semantic Scholar

   Save

3. CORRELATION BETWEEN A GENOMICS TEST AND ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY AMONG ACTIVE SURVEILLANCE CANDIDATES: PD28‐03

   P. Hurley, G. Auffenberg, J. Qi, C. Maurino +6 more

   20170 citations

   Semantic Scholar

   Save

4. 76 Radium-223 dichloride (Ra-223) improves survival in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets): nursing roles in implementing this new treatment (tx) option

   L. Causer, B. Johnson, R. Sicari, F. Lavent +4 more

   20140 citations

   Semantic Scholar

   Save